Neurological Disorder Drugs Global Market Report 2026

Description

Neurological disorder drugs are medications designed to treat conditions affecting the nervous system. These conditions can impact the brain, spinal cord, and nerves throughout the body. The medications work to control symptoms, slow disease progression, and enhance the quality of life for those affected.

The main categories of drugs used in neurological disorders include cholinesterase inhibitors, N-Methyl-D-Aspartate (NMDA) receptor antagonists, antiepileptics, antipsychotics, antidepressants, and others. Cholinesterase inhibitors are drugs that inhibit the breakdown of acetylcholine, a neurotransmitter essential for memory and cognitive function. These medications can be applied for multiple indications, such as epilepsy, Alzheimer's disease, Parkinson's disease, multiple sclerosis, cerebrovascular disease, and more, and are available through various routes of administration, including oral, parenteral, and others. They can be supplied through different distribution channels, such as hospital pharmacies, retail pharmacies, online pharmacies, and others, with end users including hospitals, specialty clinics, home care, and more.

Tariffs have influenced the neurological disorder drugs market by increasing costs for imported active pharmaceutical ingredients, intermediates, and specialized formulation materials. These impacts are most significant in regions reliant on cross-border pharmaceutical supply chains, including North America and Europe. Higher tariffs have affected pricing and availability across antiepileptic and neurodegenerative drug segments. However, tariffs have also encouraged local manufacturing, domestic API production, and supply chain diversification, supporting long-term market stability.

The neurological disorder drugs market research report is one of a series of new reports from The Business Research Company that provides neurological disorder drugs market statistics, including neurological disorder drugs industry global market size, regional shares, competitors with a neurological disorder drugs market share, detailed neurological disorder drugs market segments, market trends and opportunities, and any further data you may need to thrive in the neurological disorder drugs industry. This neurological disorder drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The neurological disorder drugs market size has grown strongly in recent years. It will grow from $89.24 billion in 2025 to $94.49 billion in 2026 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to rising prevalence of epilepsy and neurodegenerative diseases, aging global population, long-term use of symptomatic neurological drugs, expansion of hospital-based neurological care, increased diagnosis rates of neurological disorders.

The neurological disorder drugs market size is expected to see strong growth in the next few years. It will grow to $116.27 billion in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to advancements in neurological drug development pipelines, growing burden of alzheimer's and parkinson's disease, increasing access to neurological care in emerging markets, rising demand for personalized neurology treatments, expansion of homecare and outpatient neurological therapy. Major trends in the forecast period include growing adoption of disease-modifying neurological therapies, rising focus on early diagnosis and long-term disease management, increased demand for combination drug therapies, expansion of oral and home-based neurological treatments, higher emphasis on symptom management and quality of life improvement.

The rising prevalence of neurological diseases is anticipated to drive the expansion of the neurological disorder drugs market in the coming years. Neurological disorders are conditions that impact the brain, spinal cord, and nerves due to structural, biochemical, or electrical irregularities, resulting in a variety of symptoms. The growth in neurological diseases is linked to the aging global population as well as increased exposure to environmental, metabolic, and lifestyle risk factors. Neurological disorder drugs are essential in managing these complex conditions, providing symptom relief, slowing disease progression, and enhancing long-term patient outcomes. For example, in September 2024, the Australian Institute of Health and Welfare, a government agency based in Australia, projected that the number of people living with dementia in Australia will more than double between 2023 and 2058, rising from approximately 411,100 in 2023 to 849,300 by 2058, with about 315,500 men and 533,800 women affected. Consequently, the rising prevalence of neurological diseases is fueling the growth of the neurological disorder drugs market.

Major companies operating in the neurological disorder drugs market are concentrating on developing advanced solutions such as Ocrelizumab-based therapies to boost treatment effectiveness, enhance patient outcomes, and broaden therapeutic choices for individuals with multiple sclerosis. Ocrelizumab is a humanized monoclonal antibody engineered to target CD20-positive B cells, helping to reduce disease activity and slow progression in both relapsing and primary progressive forms of multiple sclerosis. For example, in September 2024, Roche Holding AG, a Switzerland-based pharmaceutical company, obtained regulatory approval from the U.S. Food and Drug Administration (FDA) for OCREVUS ZUNOVO (ocrelizumab & hyaluronidase-ocsq), a twice-yearly, roughly 10-minute subcutaneous injection, representing the first-ever subcutaneous Ocrevus formulation approved for both relapsing (RMS) and primary progressive (PPMS) multiple sclerosis. This improved delivery option is intended to enhance convenience, increase access to therapy, and support clinical workflow efficiency by providing a faster, non-intravenous method of administration.

In March 2024, Bristol-Myers Squibb Company (BMS), a US-based pharmaceutical firm, acquired Karuna Therapeutics Inc. for an undisclosed sum. With this acquisition, BMS intends to enhance its global neuroscience portfolio by obtaining Karuna's lead asset KarXT (xanomeline-trospium), a first-in-class muscarinic receptor modulator being developed for neurological and psychiatric disorders such as schizophrenia and Alzheimer's disease-related psychosis. Karuna Therapeutics Inc. is a US-based clinical-stage biopharmaceutical company focused on innovative therapies for neurological and neuropsychiatric conditions.

Major companies operating in the neurological disorder drugs market are F. Hoffmann-La Roche Ltd, Bayer AG, Sanofi S.A, AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company Pvt Ltd, Amgen Inc, Boehringer Ingelheim GmbH, Merck KGaA, Teva Pharmaceutical Industries Ltd, Otsuka America Pharmaceutical Inc, Biogen Inc, Bausch Health Companies Inc, Alexion Pharmaceuticals Inc., UCB S.A., Eisai Co Ltd, Cipla Inc, BioMarin Pharmaceutical Inc., Biocon Ltd, Acorda Therapeutics Inc.

North America was the largest region in the neurological disorder drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurological disorder drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the neurological disorder drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neurological disorder drugs market consists of sales of antiepileptic drugs, dopaminergic agents, cholinesterase inhibitors, immunomodulatory drugs, and antipsychotic drugs. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neurological Disorder Drugs Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses neurological disorder drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neurological disorder drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The neurological disorder drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

Markets Covered:1) By Drug Class: Cholinesterase Inhibitors; N-Methyl-D-Aspartate (NMDA) Receptor Antagonists; Antiepileptic; Antipsychotic And Antidepressant; Other Drugs Classes
2) By Indication: Epilepsy; Alzheimer's Disease; Parkinson's Disease; Multiple Sclerosis; Cerebrovascular Disease; Other Indications
3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
5) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End Users
Subsegments:
1) By Cholinesterase Inhibitors: Donepezil; Rivastigmine; Galantamine
2) By N-Methyl-D-Aspartate (NMDA) Receptor Antagonists: Memantine; Other NMDA Receptor Antagonists
3) By Antiepileptic: Sodium Channel Blockers; GABA Enhancers; Glutamate Modulators; Other Antiepileptics
4) By Antipsychotic and Antidepressant: Risperidone; Olanzapine; SSRIs; SNRIs; Tricyclic
5) By Other Drug Classes: Dopaminergic Drugs; Alpha-2 Agonists; Immunomodulators; Other Neurological Disorder Medications
Companies Mentioned: F. Hoffmann-La Roche Ltd; Bayer AG; Sanofi S.A; AstraZeneca PLC; Abbott Laboratories; Novartis AG; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Eli Lilly and Company Pvt Ltd; Amgen Inc; Boehringer Ingelheim GmbH; Merck KGaA; Teva Pharmaceutical Industries Ltd; Otsuka America Pharmaceutical Inc; Biogen Inc; Bausch Health Companies Inc; Alexion Pharmaceuticals Inc.; UCB S.A.; Eisai Co Ltd; Cipla Inc; BioMarin Pharmaceutical Inc.; Biocon Ltd; Acorda Therapeutics Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Product Code: PH5MNDDI01_G26Q1

1. Executive Summary

1.1. Key Market Insights (2020-2035)
1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
1.3. Major Factors Driving the Market
1.4. Top Three Trends Shaping the Market

2. Neurological Disorder Drugs Market Characteristics

2.1. Market Definition & Scope
2.2. Market Segmentations
2.3. Overview of Key Products and Services
2.4. Global Neurological Disorder Drugs Market Attractiveness Scoring And Analysis
- 2.4.1. Overview of Market Attractiveness Framework
- 2.4.2. Quantitative Scoring Methodology
- 2.4.3. Factor-Wise Evaluation
Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation
2.4.5. Strategic Implications and Recommendations

3. Neurological Disorder Drugs Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem
3.2. List Of Key Raw Materials, Resources & Suppliers
3.3. List Of Major Distributors and Channel Partners
3.4. List Of Major End Users

4. Global Neurological Disorder Drugs Market Trends And Strategies

4.1. Key Technologies & Future Trends
- 4.1.1 Biotechnology, Genomics & Precision Medicine
- 4.1.2 Artificial Intelligence & Autonomous Intelligence
- 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
- 4.1.4 Industry 4.0 & Intelligent Manufacturing
- 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
4.2. Major Trends
- 4.2.1 Growing Adoption Of Disease-Modifying Neurological Therapies
- 4.2.2 Rising Focus On Early Diagnosis And Long-Term Disease Management
- 4.2.3 Increased Demand For Combination Drug Therapies
- 4.2.4 Expansion Of Oral And Home-Based Neurological Treatments
- 4.2.5 Higher Emphasis On Symptom Management And Quality Of Life Improvement

5. Neurological Disorder Drugs Market Analysis Of End Use Industries

5.1 Hospitals
5.2 Specialty Clinics
5.3 Homecare Settings
5.4 Neurology Treatment Centers
5.5 Rehabilitation Centers

6. Neurological Disorder Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Neurological Disorder Drugs Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Neurological Disorder Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Neurological Disorder Drugs Market Size, Comparisons And Growth Rate Analysis
7.3. Global Neurological Disorder Drugs Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Neurological Disorder Drugs Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Neurological Disorder Drugs Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Neurological Disorder Drugs Market Segmentation

9.1. Global Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes
9.2. Global Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Epilepsy, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications
9.3. Global Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Oral, Parenteral, Other Routes Of Administration
9.4. Global Neurological Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
9.5. Global Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Hospitals, Specialty Clinics, Homecare, Other End Users
9.6. Global Neurological Disorder Drugs Market, Sub-Segmentation Of Cholinesterase Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Donepezil, Rivastigmine, Galantamine
9.7. Global Neurological Disorder Drugs Market, Sub-Segmentation Of N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Memantine, Other NMDA Receptor Antagonists
9.8. Global Neurological Disorder Drugs Market, Sub-Segmentation Of Antiepileptic, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Sodium Channel Blockers, GABA Enhancers, Glutamate Modulators, Other Antiepileptics
9.9. Global Neurological Disorder Drugs Market, Sub-Segmentation Of Antipsychotic and Antidepressant, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Risperidone, Olanzapine, SSRIs, SNRIs, Tricyclic
9.10. Global Neurological Disorder Drugs Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Dopaminergic Drugs, Alpha-2 Agonists, Immunomodulators, Other Neurological Disorder Medications

10. Neurological Disorder Drugs Market Regional And Country Analysis

10.1. Global Neurological Disorder Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
10.2. Global Neurological Disorder Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Neurological Disorder Drugs Market

11.1. Asia-Pacific Neurological Disorder Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Neurological Disorder Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Neurological Disorder Drugs Market

12.1. China Neurological Disorder Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Neurological Disorder Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Neurological Disorder Drugs Market

13.1. India Neurological Disorder Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Neurological Disorder Drugs Market

14.1. Japan Neurological Disorder Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Neurological Disorder Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Neurological Disorder Drugs Market

15.1. Australia Neurological Disorder Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Neurological Disorder Drugs Market

16.1. Indonesia Neurological Disorder Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Neurological Disorder Drugs Market

17.1. South Korea Neurological Disorder Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Neurological Disorder Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Neurological Disorder Drugs Market

18.1. Taiwan Neurological Disorder Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Neurological Disorder Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Neurological Disorder Drugs Market

19.1. South East Asia Neurological Disorder Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Neurological Disorder Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Neurological Disorder Drugs Market

20.1. Western Europe Neurological Disorder Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Neurological Disorder Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Neurological Disorder Drugs Market

21.1. UK Neurological Disorder Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Neurological Disorder Drugs Market

22.1. Germany Neurological Disorder Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Neurological Disorder Drugs Market

23.1. France Neurological Disorder Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Neurological Disorder Drugs Market

24.1. Italy Neurological Disorder Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Neurological Disorder Drugs Market

25.1. Spain Neurological Disorder Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Neurological Disorder Drugs Market

26.1. Eastern Europe Neurological Disorder Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Neurological Disorder Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Neurological Disorder Drugs Market

27.1. Russia Neurological Disorder Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Neurological Disorder Drugs Market

28.1. North America Neurological Disorder Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Neurological Disorder Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Neurological Disorder Drugs Market

29.1. USA Neurological Disorder Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Neurological Disorder Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Neurological Disorder Drugs Market

30.1. Canada Neurological Disorder Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Neurological Disorder Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Neurological Disorder Drugs Market

31.1. South America Neurological Disorder Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Neurological Disorder Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Neurological Disorder Drugs Market

32.1. Brazil Neurological Disorder Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Neurological Disorder Drugs Market

33.1. Middle East Neurological Disorder Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Neurological Disorder Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Neurological Disorder Drugs Market

34.1. Africa Neurological Disorder Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Neurological Disorder Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Neurological Disorder Drugs Market Regulatory and Investment Landscape

36. Neurological Disorder Drugs Market Competitive Landscape And Company Profiles

36.1. Neurological Disorder Drugs Market Competitive Landscape And Market Share 2024
- 36.1.1. Top 10 Companies (Ranked by revenue/share)
36.2. Neurological Disorder Drugs Market - Company Scoring Matrix
- 36.2.1. Market Revenues
- 36.2.2. Product Innovation Score
- 36.2.3. Brand Recognition
36.3. Neurological Disorder Drugs Market Company Profiles
- 36.3.1. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
- 36.3.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 36.3.3. Sanofi S.A Overview, Products and Services, Strategy and Financial Analysis
- 36.3.4. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
- 36.3.5. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis

37. Neurological Disorder Drugs Market Other Major And Innovative Companies

Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company Pvt Ltd, Amgen Inc, Boehringer Ingelheim GmbH, Merck KGaA, Teva Pharmaceutical Industries Ltd, Otsuka America Pharmaceutical Inc, Biogen Inc, Bausch Health Companies Inc, Alexion Pharmaceuticals Inc., UCB S.A., Eisai Co Ltd, Cipla Inc

38. Global Neurological Disorder Drugs Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Neurological Disorder Drugs Market

40. Neurological Disorder Drugs Market High Potential Countries, Segments and Strategies

40.1 Neurological Disorder Drugs Market In 2030 - Countries Offering Most New Opportunities
40.2 Neurological Disorder Drugs Market In 2030 - Segments Offering Most New Opportunities
40.3 Neurological Disorder Drugs Market In 2030 - Growth Strategies
- 40.3.1 Market Trend Based Strategies
- 40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations
41.2. Currencies
41.3. Historic And Forecast Inflation Rates
41.4. Research Inquiries
41.5. The Business Research Company
41.6. Copyright And Disclaimer